Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.
about
Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancerMitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.Gemcitabine and Vinorelbine (GemVin) RegimenRandomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.Gemcitabine in metastatic breast cancer.Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patientsPhase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer.Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors.Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
P2860
Q33340710-E22A3E04-FFDB-4A07-8EE6-3F2195DE383FQ33342718-5752C9A5-6563-4ABD-A6AC-E2E3FB6BA502Q33346610-234B83D7-4BBE-41FE-9637-E132BFB64BAFQ33371394-79943AD5-16EC-481D-8C2E-3D7FFECFB305Q33399494-8218E331-1E15-47DD-8274-6F6147AFB3DEQ33774738-2B6BE665-2DE1-45B5-A43E-BF9D42E0AE67Q34746035-0DF55599-59C2-4FF7-9379-0253CE0735B7Q36185611-2E47EEE9-9BD2-48C0-8B25-B56418C80980Q36990461-E2385E4E-C3B5-4ACC-8E1E-927D61AA43EFQ37157395-E6A23FB3-10DD-467F-BBA9-53F88114D747Q37230098-AECC719D-34EF-4992-933B-EEBFB6E48C38Q37230157-CD4ED24E-102A-471D-AC40-7C63CAB6476BQ37341664-B7D54927-71D5-4FA6-86F0-4E8604074683Q37695504-CF479ECD-CB43-421F-8671-5F5853E6E9B2Q44439083-1AED5DCF-657E-44BB-BE30-235E75EA8A9EQ50948753-0E2324CD-1420-40B7-B495-39F6AC99DC03
P2860
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@ast
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@en
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@nl
type
label
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@ast
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@en
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@nl
prefLabel
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@ast
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@en
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@nl
P2093
P356
P1433
P1476
Gemcitabine and vinorelbine as ...... ic Cooperative Oncology Group.
@en
P2093
C Kalofonos
C Nicolaides
D Bafaloukos
E Samantas
N Pavlidis
P Kosmidis
P304
P356
10.1023/A:1008361711049
P577
2000-07-01T00:00:00Z